Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564–568. https://doi.org/10.1136/gutjnl-2019-318813

Article  PubMed  Google Scholar 

Zhou XD, Cai J, Targher G et al, and Chess-MAFLD Consortium. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21(1):270. https://doi.org/10.1186/s12933-022-01697-0

Article  CAS  Google Scholar 

Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431

Article  PubMed  Google Scholar 

Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14(10):20704–20728. https://doi.org/10.3390/ijms141020704

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–1846. https://doi.org/10.1002/hep.24001

Article  CAS  PubMed  Google Scholar 

Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. https://doi.org/10.1007/s12072-020-10094-2

Article  PubMed  Google Scholar 

Jin YJ, Kim KM, Hwang S, et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. J Gastroenterol Hepatol. 2012;27(8):1341–1347. https://doi.org/10.1111/j.1440-1746.2012.07165.x

Article  CAS  PubMed  Google Scholar 

Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56(11):951–963. https://doi.org/10.1007/s00535-021-01796-x

Article  PubMed  PubMed Central  Google Scholar 

Wong VW, Chan RS, Wong GL, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013;59(3):536–542. https://doi.org/10.1016/j.jhep.2013.04.013

Article  PubMed  Google Scholar 

Shojaee-Moradie F, Cuthbertson DJ, Barrett M, et al. Exercise training reduces liver fat and increases rates of VLDL clearance but not VLDL production in NAFLD. J Clin Endocrinol Metab. 2016;101(11):4219–4228. https://doi.org/10.1210/jc.2016-2353

Article  CAS  PubMed  Google Scholar 

Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–511. https://doi.org/10.1016/j.soard.2018.12.002

Article  PubMed  Google Scholar 

Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176–1184. https://doi.org/10.1053/j.gastro.2008.06.047

Article  CAS  PubMed  Google Scholar 

Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–2307. https://doi.org/10.1056/NEJMoa060326

Article  CAS  PubMed  Google Scholar 

Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305–315. https://doi.org/10.7326/M15-1774

Article  PubMed  Google Scholar 

Della Pepa G, Russo M, Vitale M, et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract. 2021;178:108984. https://doi.org/10.1016/j.diabres.2021.108984

Article  CAS  PubMed  Google Scholar 

Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–1685. https://doi.org/10.1056/NEJMoa0907929

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoneda M, Honda Y, Ogawa Y et al. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diabetes Res Care. 2021;9(1). https://doi.org/10.1136/bmjdrc-2020-001990

Boettcher E, Csako G, Pucino F, et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35(1):66–75. https://doi.org/10.1111/j.1365-2036.2011.04912.x

Article  CAS  PubMed  Google Scholar 

Tolman KG, Freston JW, Kupfer S, et al. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf. 2009;32(9):787–800. https://doi.org/10.2165/11316510-000000000-00000

Article  CAS  PubMed  Google Scholar 

Bouchi R, Terashima M, Sasahara Y, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16(1):32. https://doi.org/10.1186/s12933-017-0516-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cusi K, Bril F, Barb D, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(4):812–821. https://doi.org/10.1111/dom.13584

Article  CAS  PubMed  Google Scholar 

Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15(3):181–187. https://doi.org/10.1007/s11154-014-9289-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akuta N, Kawamura Y, Fujiyama S, et al. SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology. Intern Med. 2020;59(16):1931–1937. https://doi.org/10.2169/internalmedicine.4398-19

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akuta N, Watanabe C, Kawamura Y, et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017;1(1):46–52. https://doi.org/10.1002/hep4.1019

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akuta N, Kawamura Y, Watanabe C, et al. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res. 2019;49(5):531–539. https://doi.org/10.1111/hepr.13304

Article  CAS  PubMed  Google Scholar 

Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021;12(3):843–861. https://doi.org/10.1007/s13300-021-01011-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyake T, Yoshida S, Furukawa S, et al. Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Med (Wars). 2018;13:402–409. https://doi.org/10.1515/med-2018-0059

Article  CAS  PubMed  Google Scholar 

Takahashi H, Kessoku T, Kawanaka M, et al. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun. 2022;6(1):120–132. https://doi.org/10.1002/hep4.1696

Article  CAS  PubMed  Google Scholar 

Yamashima M, Miyaaki H, Miuma S, et al. The long-term efficacy of sodium glucose co-transporter 2 inhibitor in patients with non-alcoholic fatty liver disease. Intern Med. 2019;58(14):1987–1992.